×ÉѯÈÈÏß
18616108315
18616108315
²úÎï·ÖÀà
Product CategoryÏêϸ½éÉÜ
| Æ·ÅÆ | ³¢¾±´Ú±ð-¾±³¢²¹²ú/Àî¼ÇÉúÎï |
|---|
²úÎïÃèÊö
4T1£¨ÖÐÎÄÃû³Æ£ºÐ¡ÊóÈéÏÙ°©Ï¸°û£©£¬À´Ô´ÓÚСÊóÈéÏÙÏÙ°©£¬Õý³£µÄϸ°ûÐÎ̬ΪÉÏƤÑù£¬Ìù±ÚÉú³¤¡£
¶©¹ºÐÅÏ¢
²úÎïÃû³Æ | »õºÅ | ¹æ¸ñ |
4T1 | AX31L184 | T25/1 mL |
ÔËÊ䷽ʽ
³£ÎÂ/¸É±ùÔËÊä¡£
ʹÓ÷½·¨
ÅàÑø·½·¨
ÅàÑø»ù | RPMI-1640 90%(Gibco: C11875500BT), Fetal Bovine Serum(GIBCO:10099-141)»òºÍÔªÀî¼ÇÌؼ¶Ì¥Å£ÑªÇå (Foetal Bovine Serum)£¨»õºÅ£ºAC03L055£© 10% |
ÅàÑøÌõ¼þ | 37¡æ 5% CO2 |
Ïû»¯Ìõ¼þ | 0.25% (w/v) Trypsin-0.53mM EDTAÈÜÒº(GIBCO: 25200-056) »ò ºÍÔªÀî¼Ç0.25%Òȵ°µÄ°×øÏû»¯Òº£¨º¬EDTA£¬²»º¬·Óºì£©£¨»õºÅ£ºAC15L821£©£¬Ïû»¯1-3min |
´«´ú±ÈÀý | 1£º3-1£º5 |
»»ÒºÊ±¼ä | 2-3Ìì»»ÒºÒ»´Î |
¶³´æ·½·¨
¶³´æÒº | 55%ÅàÑø»ù£¬40%FBS, 5% (v/v) DMSO»ò ºÍÔªÀî¼Ç¿ìËÙϸ°û¶³´æÒº£¨ÎÞѪÇå¡¢ÎÞµ°°×£©£¨»õºÅ£ºAC05L033£© |
¶³´æÃÜ¶È | 1-3 ¡Á106 /¹Ü£¬Òºµª±£´æ |
¡¡ ¾ßÌå²Ù×÷·½·¨¼ûϸ°ûʹÓÃ˵Ã÷Êé
×¢ÒâÊÂÏî
±¾²úÎï½öÏÞÓÚ¿ÆѧʵÑéÑо¿Ê¹Ó㬲»µÃÓÃÓÚÁÙ´²Õï¶Ï¡¢ÖÎÁƵÈÁìÓò¡£
µ±ÊÕµ½Ï¸°ûºó£¬Çë×ÐϸÔĶÁϸ°ûʹÓÃ˵Ã÷Ê飬°´¹æ¶¨²Ù×÷²¢¼Ç¼ϸ°û״̬£¨ÅÄÕÕ£©¡£ÎÒ˾Ϊ¿Í»§ÌṩһÖÜÄÚµÄÊÛºó±£ÕÏ£¬Ìض¨Çé¿öÏ¿ÉÃâ·ÑÖØ·¢Ï¸°û¡£
²Î¿¼ÎÄÏ×
Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864
Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252
Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145
Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948
Ïà¹Ø²úÎïÍƼö
Ìؼ¶Ì¥Å£ÑªÇå (Foetal Bovine Serum)£¨»õºÅ£ºAC03L055£©
RPMI-1640 medium (º¬L-¹È°±µÄõ£°·)£¨»õºÅ£ºAC01L064£©
±¾²úÎï½öÏÞÓÚ¿ÆѧʵÑéÑо¿Ê¹Ó㬲»µÃÓÃÓÚÁÙ´²Õï¶Ï¡¢ÖÎÁƵÈÁìÓò¡£
²úÎï×Éѯ
΢ÐÅ×Éѯµç»°
΢ÐÅ×Éѯ
¹Ø×¢¹«ÖÚºÅ
µ±Ç°Î»Öãº
